{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Exon+20", "query": { "condition": "Exon 20" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Exon+20&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T19:07:03.316Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05668988", "title": "A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "sunvozertinib", "type": "DRUG" }, { "name": "Pemetrexed+carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dizal Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2022-12-13", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 14, "location_summary": "Glendale, California • Vallejo, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Margate", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05668988" }, { "nct_id": "NCT03744715", "title": "A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Breast Cancer" ], "interventions": [ { "name": "Poziotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2018-10-05", "completion_date": "2023-03-03", "has_results": false, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 5, "location_summary": "Long Beach, California • Hattiesburg, Mississippi • New York, New York + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Hattiesburg", "state": "Mississippi" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03744715" }, { "nct_id": "NCT05315700", "title": "Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ORIC-114", "type": "DRUG" }, { "name": "Chemotherapy drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2022-03-10", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 17, "location_summary": "Duarte, California • Huntington Beach, California • Irvine, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05315700" }, { "nct_id": "NCT06043817", "title": "First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "NSCLC", "EGFR/HER2 Exon 20 Insertion Mutation" ], "interventions": [ { "name": "STX-721/PFL-721 (Escalated)", "type": "DRUG" }, { "name": "STX-721/PFL-721 (3 dose levels)", "type": "DRUG" }, { "name": "STX-721/PFL-721 (RP2D)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2023-09-26", "completion_date": "2029-12-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 9, "location_summary": "Duarte, California • Huntington Beach, California • Irvine, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06043817" }, { "nct_id": "NCT05607550", "title": "Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer", "Advanced Non-Small Cell Lung Cancer", "EGFR Exon 20 Mutations" ], "interventions": [ { "name": "furmonertinib 240 mg oral, daily", "type": "DRUG" }, { "name": "furmonertinib 160 mg oral, daily", "type": "DRUG" }, { "name": "platinum-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArriVent BioPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2023-06-01", "completion_date": "2028-02-15", "has_results": false, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 69, "location_summary": "Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05607550" }, { "nct_id": "NCT07229339", "title": "Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Squamous Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Zipalertinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2027-06-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07229339" }, { "nct_id": "NCT05048797", "title": "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "123 Years", "sex": "ALL", "summary": "18 Years to 123 Years" }, "enrollment_count": 454, "start_date": "2021-10-28", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 19, "location_summary": "Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05048797" }, { "nct_id": "NCT05498389", "title": "EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "EGFR Mutation-Related Tumors" ], "interventions": [ { "name": "EMB-01", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2023-06", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 2, "location_summary": "Orange, California • Boston, Massachusetts", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05498389" }, { "nct_id": "NCT07128199", "title": "A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NSCLC, Stage IB-IIIA", "Lung Cancer", "Adjuvant", "Post-surgical", "EGFR", "Exon 20", "Early Stage Lung Cancer", "Uncommon EGFR Mutations" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "TAS6417", "type": "DRUG" }, { "name": "Zipalertinib Matching-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-12-22", "completion_date": "2032-10-01", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 30, "location_summary": "Anchorage, Alaska • Duarte, California • Irvine, California + 26 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128199" }, { "nct_id": "NCT03066206", "title": "Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EGFR Exon 20 Mutation", "ERBB2 Gene Mutation", "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7" ], "interventions": [ { "name": "Poziotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2017-03-17", "completion_date": "2026-02-16", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-06-25T19:07:03.316Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03066206" } ] }